Teva Pharmaceutical Industries Limited

OTCPK:TEVJF

Ισραήλ / Υγεία / Φαρμακευτικά

Επισκόπ.

Μερίσματα

Κέρδη

Μοντέλα

Οικονομικές Καταστάσεις

Σύγκριση

Υγεία

Διαγράμματα

Ιστορικό οικ. καταστάσεων 5 ετ.

Τιμή μετοχής

14,80 USD


Key Metrics	Latest
Total Revenue	16,544 B
Adjusted EBITDA	4,431 B
EBITDA Margin	26,8%
Net Profit Margin	4,6%
Total Assets	39,326 B
Total Debt	18,184 B

5Y Historical Financial Statements

Summary Financials


Summary Financials

	Fiscal Year Ending					Latest	Year-to-date Ending
(in millions)	Dec-20	Dec-21	Dec-22	Dec-23	Dec-24	12 Months	Dec-23	Dec-24

Revenue	16,659.00	15,878.00	14,925.00	15,846.00	16,544.00	16,544.00	15,846.00	16,544.00
% Growth		(0.05)	(0.06)	0.06	0.04			0.04

Adjusted EBITDA	4,612.00	4,409.00	3,970.00	4,333.00	4,431.00	4,431.00	4,333.00	4,431.00
% Margin	0.28	0.28	0.27	0.27	0.27	0.27	0.27	0.27

Adjusted EBIT	3,055.00	3,079.00	2,662.00	3,180.00	3,372.00	3,372.00	3,180.00	3,372.00
% Margin	0.18	0.19	0.18	0.20	0.20	0.20	0.20	0.20

Adjusted Net Income	804.24	1,531.96	1,096.66	1,417.78	760.50	760.50	1,417.78	760.50
% Margin	0.05	0.10	0.07	0.09	0.05	0.05	0.09	0.05

Adjusted Basic EPS	0.73	1.39	0.99	1.27	0.67	0.67	1.27	0.67

Υποστηρικτικοί υπολογισμοί

Income Statement

Balance Sheet

Statement of Cashflows


Income Statement
						Original
USD	Fiscal Year Ending					Latest	Year-to-date Ending
(in millions)	Dec-20	Dec-21	Dec-22	Dec-23	Dec-24	Dec-24	Dec-23	Dec-24
	FY - 4	FY - 3	FY - 2	FY - 1	FY	LTM	YTD-1	YTD

Revenue	16,659	15,878	14,925	15,846	16,544	16,544	15,846	16,544
% Growth	NA	-4.7%	-6.0%	6.2%	4.4%			4.4%

Cost of Revenue	(8,933)	(8,284)	(7,952)	(8,200)	(8,481)	(8,481)	(8,200)	(8,481)
Gross Profit	7,726	7,594	6,973	7,646	8,063	8,063	7,646	8,063
% Revenue	46.4%	47.8%	46.7%	48.3%	48.7%	48.7%	48.3%	48.7%

Research and Development	(1,794)	(1,094)	(883)	(1,043)	(1,055)	(1,055)	(1,043)	(1,055)
Selling and Marketing	(2,498)	(2,429)	(2,265)	(2,336)	(2,541)	(2,541)	(2,336)	(2,541)
General and Admin	(1,173)	(1,099)	(1,180)	(1,162)	(1,161)	(1,161)	(1,162)	(1,161)
Other Inc / (Exp)	(5,731)	(1,414)	(4,867)	(2,766)	(3,673)	(3,673)	(2,766)	(3,673)
Total Operating Exp	(11,196)	(6,036)	(9,195)	(7,307)	(8,430)	(8,430)	(7,307)	(8,430)

Operating Income	(3,470)	1,558	(2,222)	339	(367)	(367)	339	(367)
% Revenue	-20.8%	9.8%	-14.9%	2.1%	-2.2%	-2.2%	2.1%	-2.2%

Interest Expense	(797)	(891)	(920)	(961)	(916)	(916)	(961)	(916)
Pre-tax Income	(4,267)	667	(3,142)	(622)	(1,283)	(1,283)	(622)	(1,283)
Earnings of Discontinued Ops.	0	0	0	0	0	0	0	0
Provision for Taxes	168	(211)	643	7	(676)	(676)	7	(676)
Net Income to Company	(4,099)	456	(2,499)	(615)	(1,959)	(1,959)	(615)	(1,959)
% Margin	-24.6%	2.9%	-16.7%	-3.9%	-11.8%	-11.8%	-3.9%	-11.8%

Minority Interest in Earnings	109	(39)	53	56	320	320	56	320
Net Income to Stockholders	(3,990)	417	(2,446)	(559)	(1,639)	(1,639)	(559)	(1,639)

Preferred Dividends	0	0	0	0	0	0	0	0
Other Adj.	0	0	0	0	0	0	0	0

Net Income to Common	(3,990)	417	(2,446)	(559)	(1,639)	(1,639)	(559)	(1,639)
% Margin	-24.0%	2.6%	-16.4%	-3.5%	-9.9%	-9.9%	-3.5%	-9.9%

As Reported
Basic EPS (Continuing Ops)	(3.64)	0.38	(2.20)	(0.50)	(1.45)	(1.45)	(0.50)	(1.45)
Diluted EPS (Continuing Ops)	(3.64)	0.38	(2.20)	(0.50)	(1.45)	(1.45)	(0.50)	(1.45)

WA Basic Shares Out.	1,095.00	1,102.00	1,110.00	1,119.00	1,131.00	1,131.00	1,119.00	1,131.00
WA Diluted Shares Out.	1,095.00	1,107.00	1,110.00	1,119.00	1,131.00	1,131.00	1,119.00	1,131.00

EBITDA, EBIT Reconciliation
EBT, Incl. Unusual Items	(4,267)	667	(3,142)	(622)	(1,283)	(1,283)	(622)	(1,283)
Addback: Net Interest Expense	797	891	920	961	916	916	961	916
Addback: Other Non Operating Expenses, Total	(101)	67	25	94	64	64	94	64
Addback: Depreciation & Amortization	1,557	1,330	1,308	1,153	1,059	1,059	1,153	1,059
Addback: Restructuring Charges	120	133	146	111	74	74	111	74
Addback: Merger / Acquisition Expenses	0	0	0	0	0	0	0	0
Addback: Goodwill Impairment	4,628	0	2,045	700	1,280	1,280	700	1,280
Addback: Gain (Loss) On Sale Of Invest.	0	90	0	0	0	0	0	0
Addback: Gain (Loss) On Sale Of Assets	(19)	(58)	(64)	(28)	(17)	(17)	(28)	(17)
Addback: Asset Writedown	1,918	584	402	378	1,275	1,275	378	1,275
Addback: In Process R&D Expenses	0	0	0	0	0	0	0	0
Addback: Insurance Settlements	0	0	0	0	0	0	0	0
Addback: Legal Settlements	60	698	2,069	1,038	760	760	1,038	760
Addback: Other Unusual Items	(81)	7	261	548	303	303	548	303
Adjusted EBITDA	4,612	4,409	3,970	4,333	4,431	4,431	4,333	4,431
% Margin	27.7%	27.8%	26.6%	27.3%	26.8%	26.8%	27.3%	26.8%

Adjusted EBIT	3,055	3,079	2,662	3,180	3,372	3,372	3,180	3,372
% Margin	18.3%	19.4%	17.8%	20.1%	20.4%	20.4%	20.1%	20.4%

Adjusted Net Income Reconciliation
Net Income to Company	(4,099)	456	(2,499)	(615)	(1,959)	(1,959)	(615)	(1,959)
Addback: Unusual Items	6,626	1,454	4,859	2,747	3,675	3,675	2,747	3,675
Less: Tax Benefit of Unusual Items (26%)	(1,723)	(378)	(1,263)	(714)	(956)	(956)	(714)	(956)
Adjusted Net Income	804	1,532	1,097	1,418	761	761	1,418	761
% Margin	4.8%	9.6%	7.3%	8.9%	4.6%	4.6%	8.9%	4.6%

Με επιφύλαξη παντός δικαιώματος. Όροι Χρήσης

Σφάλμα φόρτωσης

Teva Pharmaceutical Industries Limited

OTCPK:TEVJF

Ισραήλ / Υγεία / Φαρμακευτικά

Ιστορικό οικ. καταστάσεων 5 ετ.